Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue

Multiple Sclerosis

Volumn 12, Issue 3, 2006, Pages 321-324

  Lebrun, Christine ^a   Alchaar, H ^a   Candito, M ^a   Bourg, V ^a   Chatel, M ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

Carnitine; Cyclophosphamide; Fatigue; Interferon; Mitoxantrone; Multiple sclerosis

Indexed keywords

ACYLCARNITINE; BETA INTERFERON; CARNITINE; CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; MITOXANTRONE;

ADOLESCENT; ADULT; ARTICLE; CARNITINE DEFICIENCY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; FATIGUE; FEMALE; FREQUENCY ANALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OPEN STUDY; PLASMA; RELAPSE; STATISTICAL ANALYSIS; SYMPTOM; TREATMENT OUTCOME;

ACETYLCARNITINE; ADOLESCENT; ADULT; CYCLOPHOSPHAMIDE; FATIGUE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NOOTROPIC AGENTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33744827375     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1275oa     Document Type: Article

References (18)

1. Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer 2002; 86: 1854-57.
2. Peluso G, Nicolai R, Reda E, Benatti P, Barbarisi A, Calvani M. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol 2000; 182: 339-50.
3. Sayed-Ahmed MM, Shaarawy S, Shouman SA, Osman AMM. Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacol Res 1999; 39: 289-95.
4. Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 1997; 35: 16-23.
5. Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann NY Acad Sci 2004; 1033: 168-76.
6. Marthaler NP, Visarius T, Kupfer A, Lauterburg BH. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol 1999; 44: 170-72.
7. Sima AA, Calvani M, Mehra M, Amato A. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-control trials. Diabetes Care 2005; 28: 89-94.
8. Pistone G, Marino AD, Leotta C, Dell'Arte S, Finocchario G, Malaguarnera M. Levocarnitine administration in elderly subjects with rapid muscle fatigue. Drugs Aging 2003; 20: 761-67.
9. Cederblad G, Harper P, Lindgren K. Spectrometry of carnitine in biological fluids and tissue with a Kone analyser. Clin Chem 1986; 32: 342-46.
10. Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X. Does the modified fatigue impact scale offer a more comprehensive assessment of fatigue in MS? Mult Scler 2005; 11: 198-202.
11. Krupp LB, Alvarez LA, La Rocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol 1998; 45: 435-37.
12. Hommes OR, Weiner HL. Results of an international questionnaire on immunosuppressive treatment of MS. Mult Scler 2002; 8: 139-41.
13. Romani A, Bergamaschi R, Candeloro E, Alfonsi E, Callieco R, Cosi V. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. Mult Scler 2004; 10: 462-68.
14. Steinherz LJ. Anthracycline-induced cardiotoxicity. Ann Intern Med 1997; 126: 827.
15. Fukazawa T, Saski H, Kikuchi S, Hamada T, Tashiro K. Serum carnitine and disabling fatigue in multiple sclerosis. Psychiatry Clin Neurosci 1996; 50: 323-25.
16. Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double blind, cross-over trial. J Neurol Sci 2003; 218: 103-108.
17. Neri S, Pistone G, Saraceno B, Pennisi G, Luca S, Malaguanera M. L-carnitine decreases severity and type of fatigue induced by interferon alpha in the treatment of patients with hepatitis C. Neuropsychology 2003; 47: 94-97.
18. Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, Patry DG et al. Effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry 2004; 75: 1045-47.